Mankind Pharma Limited — Updates, 05-11-2024: Press Release

Mankind Pharma reported a strong Q2 FY25, with revenue rising 14% YoY to INR 3,077 crore and a 29% increase in PAT to INR 659 crore. EBITDA margin improved to 27.7%. The company’s domestic revenue grew 11% YoY, while exports surged 57%. Growth in its consumer healthcare segment was notable, showcasing a 20% YoY increase. Key initiatives include spinning off its OTC business and acquiring a prominent player in the gynaecology segment to enhance R&D capabilities.